City Therapeutics (CTY) closed at $20.43 on October 21, 2026, down 1.9% from the previous close, on volume of 277,591 shares (30-day average 751,624).
Data as of October 21, 2026.
Globe Newswire (Mon, 19-Oct 4:01 PM ET)
RNAi drug developer City climbs after upsized IPO
Seeking Alpha News (Fri, 16-Oct 1:24 PM ET)
RNAi drugmaker City prices upsized IPO at $18 per share
Seeking Alpha News (Fri, 16-Oct 9:51 AM ET)
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
City Therapeutics trades on the NASDAQ stock market under the symbol CTY.
As of October 21, 2026, CTY stock price declined to $20.43 with 277,591 million shares trading.
CTY has a market cap of $1.03 billion. This is considered a Small Cap stock.
CTY support price is $20.08 and resistance is $21.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTY shares will trade within this expected range on the day.
